Kymera Therapeutics Inc (KYMR) 뉴스

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models...

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven...

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall...

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities